Monthly
Issues
2003: March; April,
May, June, July, August, September, October, November, December
2004: January,
February, March, April, May, June, July, August, September, October, November, December
2005: January, February, March, April, May, June, July, August, September, October, November,
December
2006: January, February
|
Special
Issues
|
|
2003 EASL Meeting Highlights
2003 Clinical Experts Panel Meeting
Highlights
2004 AASLD Single
Topic Meeting: New Directions in the
Treatment of Hepatitis B
2004 EASL Meeting Highlights
2005 DDW Abstract Highlights
|
Topic
Listing
|
|
REVIEWS
§
Antiviral prophylaxis of
HBV carriers who receive immunosuppressive or cytotoxic chemotherapy
§
Antiviral
therapy for prevention of perinatal HBV transmission
§
Chronic hepatitis B and
kidney transplantation
§
Coinfection with hepatitis B
virus and human immunodeficiency virus
§
HBsAg seroclearance:
Outcomes in Chinese patients
§
Healthcare workers who
are chronically infected with hepatitis B virus
§
Hepatitis B Vaccine
Nonresponse
§
Hepatitis B virus (HBV)
DNA levels and hepatocellular carcinoma
§
Noninvasive surrogate
markers of hepatitis B virus (HBV) fibrosis
§
Treatment of chronic
hepatitis B in the human immunodeficiency virus (HIV)-infected patient
|
|
ACUTE
SELF-LIMITED HBV INFECTION
§
Long
term outcomes
|
|
ACUTE
EXACERBATION OF HBV INFECTION
§
Population
study of spontaneous HBeAg seroconversion
|
|
ADEFOVIR
DIPIVOXIL
§
Adefovir dipivoxil therapy
§
Adefovir resistance: Association with viral rebound and hepatic
decompensation
§
Development of an HBV polymerase mutation and clinical resistance
§
Genotype and viral
response
§
Resistance surveillance
§
Results of treatment in lamivudine-resistant HBV
infection
§
Treatment
of HBeAg-negative chronic hepatitis B
§
Treatment
of HBeAg-positive chronic hepatitis B
|
|
ANTIBODY TO HEPATITIS B SURFACE ANTIGEN
(Anti-HBs)
§
Development of anti-HBs
after liver transplantation
|
|
ANTIVIRAL THERAPY
§
Treatment of hepatitis B and
C dual infection
|
|
BIOCHEMICAL MARKERS IN HBV PATIENTS
§
Prediction of histological lesions
|
|
CHILDHOOD CHRONIC HBV
•
Current therapeutic approaches
|
|
COINFECTION WITH HEPATITIS B AND HUMAN
IMMUNODEFICIENCY VIRUS
§
Adefovir
dipivoxil therapy for HBV/human immunodeficiency virus–1 (HIV-1)
coinfection
§
Impact of HBV coinfection on
outcomes of HIV patients
|
|
EPIDEMIOLOGY
§
Changes
in a US community
§
Genotype and precore/core variants
§
Healthcare-related viral
hepatitis transmission
|
|
HBeAg
§
Correlation with serum HBV
DNA levels
§
Different mechanisms of
HBeAg seroconversion
§
Meaning of HBeAg and
significance of HBV levels
§
Long-term adefovir
dipivoxil therapy in HBeAg negative patients
§
Long-term lamivudine
therapy in HBeAg negative patients
§
Peginterferon alfa-2a vs
lamivudine in HBeAg positive patients
|
|
HBsAg
§
Maternal
HBsAg carrier status and pregnancy outcomes
|
HBV-Associated Polyarteritis Nodosa
§
Clinical characteristics and outcome
|
HBV GENOTYPE TESTING
§
Topic Review: Research tool
or ready for “prime time”
|
HBV REACTIVATION
|
HBV VACCINATION
§
Hepatitis A and B vaccination:
Adherence to guidelines
§
Lack of association with multiple sclerosis
§
Long-term follow-up of a randomized trial
§
Need for boosters and
significance of HBsAg escape mutants
§
Newborn vaccination program in Taiwan
§
Protection
after 15 years of follow-up
|
HBV REPLICATION
§
Covalently closed circular DNA (cccDNA)
|
HBV-RELATED ACUTE LIVER FAILURE
§
Virologic characteristics
|
hbv transmission
§
HBV
DNA levels in serum, saliva, and urine
§
Laboratory-based screening
of health care workers
|
HEPATOCELLULAR CARCINOMA
§
Association with HBV DNA level
and genotype
§
Effectiveness of prophylactic lamivudine administration
§
HBV mode of transmission
§
HBV reactivation
§
Occult HBV as a possible risk factor
for HCC
§
Prospective study of Taiwanese children
with chronic HBV infection
§
Role of reproductive factors
§
Risk of HBV exacerbation after transcatheter arterial
chemoembolization
§
Woodchuck hepatitis virus (WHV) animal model and N-myc rearrangements
|
IMMUNOPROPHYLAXIS
§
Long-term results following liver
transplantation
|
Interferon Therapy
§
A study of individualized
therapy
§
Impact on liver fibrosis
progression
§
Long-term
follow-up
§
Long-term suppression
§
Peginterferon alfa-2b alone
or with lamivudine in patients with HBeAg-positive chronic hepatitis B
§
Staggered regimen of peginterferon alfa-2b and lamivudine in
patients with HBeAg-positive chronic hepatitis B
|
Lamivudine therapy
§
Compassionate use
§
Determinants for sustained response
§
Durability of response
§
Early therapy for HBV
patients undergoing chemotherapy is superior
§
Extended treatment following seroconversion
§
In
hepatic decompensation
§
Histological outcomes
§
LAM-containing therapy for
IFN nonresponders
§
LAM vs. LAM + hepatitis B
immune globulin (HBIg) to prevent post-transplant HBV recurrence
§
Treatment of patients with advanced liver disease
§
Tenofovir disoproxil treatment
§
Long-term follow-up of peginterferon and lamivudine combination
therapy
§
Long-term safety
§
Long-term treatment enhances durability of HBeAg loss
§
Results of 2 years of treatment in patients with HBeAg-negative HBV
infection
§
Transient
restoration of antiviral T-cell responses
§
Treatment of acute, severe hepatitis B
§
Treatment of children
|
LAMIVUDINE RESISTANT hbv
§
Comparison of adefovir and tenofovir
§
Immunoglobulin M (IgM) antibody to
hepatitis B core antigen (anti-HBc) predicts poor response to lamivudine
§
Timing of adefovir dipivoxil
(ADV) therapy for lamivudine-resistant hepatitis B virus
|
LIVER TRANSPLANTATION
§
Adjuvant hepatitis B vaccine
§
HBV vaccine permits withdrawal of HBIG prophylaxis
§
Improved outcome
§
Outcomes of HCV antibody-positive and
hepatitis B core antibody-positive grafts
§
Prevention
of HBV reinfection after liver transplantation
§
Prophylaxis of HBV recurrence
|
MECHANISMS OF CHRONIC hbv INFECTION
§
Defective dendritic cell
-T cell interaction
|
|
NATURAL HISTORY OF HBV INFECTION
§
Cohort study in northern Greece
§
Follow-up of patients from an early stage of HBV infection
§
Genotype C vs genotype B infection
|
|
NEW THERAPEUTIC AGENTS
§
Analysis of long-term
emtricitabine trials
§
Dose-escalating trial
of clevudine
§
Phase II dose-finding
study of emtricitabine
§
Telbivudine trial
|
|
NON-INVASIVE TESTS IN HBV PATIENTS
§
13C-caffeine breath test
§
FT-AT
§
Noninvasive model to
predict significant fibrosis
|
|
NOSOCOMIAL HBV INFECTION
§
HBV and HCV infection in a
pediatric ward
|
NUCLEIC
ACID TESTING (NAT) FOR HBV INFECTION
§
Technological improvement
and automation
|
OCCULT
HBV INFECTION
§
Occult HBV in hemodialysis patients
|
PEDIATRIC
CHRONIC HBV INFECTION
§
Predictors of virological response
to lamivudine therapy
|
PEDIATRIC
FULMINANT HEPATIC FAILURE
§
Follow-up 15 years after
universal hepatitis B vaccination
|
PEGINTERFERON
(PEG-IFN) ALFA-2A THERAPY
§
First report on treatment of
chronic hepatitis B
§
Peginterferon alfa-2a
versus lamivudine in HBeAg-negative patients
|
PERINATAL
TRANSMISSION OF HBV
§
Analysis of HBV DNA levels and HBeAg titers in Chinese mothers and
their babies
|
OUTCOME
OF HBV THERAPY
§
Durability of
treatment-induced HBeAg seroconversion
|
PROGNOSTIC
FACTORS
§
Prognostic
determinants in Asian patients with chronic HBV
§
Relation
of HBV flares to treatment response
§
Risk factors for the development of
complications in Asian HBV patients
§
The influence of genotype
on virologic outcomes
|
RENAL
TRANSPLANTATION
§
HBV in renal transplant
recipients
|
RISK
FACTORS FOR HBV REACTIVATION
§
Cancer patients
undergoing cytotoxic chemotherapy
§
Occurrence during chemotherapy
for hematologic malignancies
§
Occurrence after
infliximab therapy for Crohn's disease
§
Association with
disappearance of anti-HBs following allogeneic hematopoietic stem cell
transplantation
|
RANDOMIZED
STUDIES
§
Dose-finding study of
once-daily oral telbivudine in HBeAg-positive patients with chronic HBV
infection
§
Entecavir
dose-ranging study
§
Steroid-free chemotherapy
and the risk of HBV reactivation
§
Serum HBV DNA as marker
for treatment efficacy
|
SUPERINFECTION
§
Impact of acute hepatitis C in patients with chronic HBV infection
|
THYMALFASIN
§
Efficacy and safety of thymalfasin
|
TRANSPLANTATION
§
Subclinical reactivation of HBV
|
TREATMENT
GUIDELINES
§
Recommended updates
|
